Alliancebernstein L.P. Relmada Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $27,125 - $448,000	12,500 Added 69.83%	30,400 $106,000
Q3 2022 Nov 15, 2022	SELL	$18.3 - $37.02 $1.08 Million - $2.19 Million	-59,132 Reduced 76.76%	17,900 $663,000
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $975,678 - $1.79 Million	59,132 Added 330.35%	77,032 $1.46 Million
Q2 2021 Jul 30, 2021	BUY	$29.55 - $39.15 $65,010 - $86,130	2,200 Added 14.01%	17,900 $573,000
Q4 2020 Feb 08, 2021	SELL	$29.88 - $39.8 $50,796 - $67,660	-1,700 Reduced 9.77%	15,700 $503,000
Q3 2020 Nov 12, 2020	SELL	$34.42 - $43.78 $20,652 - $26,268	-600 Reduced 3.33%	17,400 $655,000
Q2 2020 Aug 13, 2020	BUY	$31.59 - $49.98 $568,620 - $899,640	18,000 New	18,000 $806,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.